<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33654796</PMID><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2331-8325</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Bio-protocol</Title><ISOAbbreviation>Bio Protoc</ISOAbbreviation></Journal><ArticleTitle>Production and Purification of Dengue Virus-like Particles from COS-1 Cells.</ArticleTitle><Pagination><StartPage>e3280</StartPage><MedlinePgn>e3280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e3280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21769/BioProtoc.3280</ELocationID><Abstract><AbstractText>Non-infectious virus-like particles (VLPs) containing dengue virus (DENV) pre-membrane (prM) and envelope (E) proteins have been demonstrated to be highly immunogenic and can be used as a potential vaccine candidate as well as a tool for serodiagnostic assays. Successful application of VLPs requires abundant, and high-purity production methods. Here, we describe a robust protocol for producing DENV VLPs from transiently-transformed or stable COS-1 cells and further provide an easily adaptable antigen purification method by sucrose gradient centrifugation.</AbstractText><CopyrightInformation>&#xa9;Copyright Galula et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galula</LastName><ForeName>Jedhan Ucat</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Day-Yu</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bio Protoc</MedlineTA><NlmUniqueID>101635102</NlmUniqueID><ISSNLinking>2331-8325</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COS-1 cell</Keyword><Keyword MajorTopicYN="N">Dengue virus (DENV)</Keyword><Keyword MajorTopicYN="N">Sucrose gradient centrifugation</Keyword><Keyword MajorTopicYN="N">VLP purification</Keyword><Keyword MajorTopicYN="N">Virus-like particle (VLP)</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33654796</ArticleId><ArticleId IdType="pmc">PMC7854098</ArticleId><ArticleId IdType="doi">10.21769/BioProtoc.3280</ArticleId><ArticleId IdType="pii">e3280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allison S. L., Stadler K., Mandl C. W., Kunz C. and Heinz F. X.(1995). Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 69(9): 5816-5820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189449</ArticleId><ArticleId IdType="pubmed">7637027</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G. J., Hunt A. R. and Davis B.(2000). A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J Virol 74(9): 4244-4252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111940</ArticleId><ArticleId IdType="pubmed">10756038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G. J., Hunt A. R., Holmes D. A., Springfield T., Chiueh T. S., Roehrig J. T. and Gubler D. J.(2003). Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306(1): 170-180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12620809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao D. Y., Whitney M. T., Davis B. S., Medina F. A., Munoz J. L. and Chang G. J.(2019). Comprehensive evaluation of differential serodiagnosis between Zika and Dengue viral infections. J Clin Microbiol 57(3): e01506-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425182</ArticleId><ArticleId IdType="pubmed">30541932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou S. S., Crill W. D., Chen L. K. and Chang G. J.(2008). Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol 15(5): 825-835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2394851</ArticleId><ArticleId IdType="pubmed">18337381</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill W. D., Hughes H. R., Delorey M. J. and Chang G. J.(2009). Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4(4): e4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis B. S., Chang G. J., Cropp B., Roehrig J. T., Martin D. A., Mitchell C. J., Bowen R. and Bunning M. L.(2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75(9): 4040-4047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114149</ArticleId><ArticleId IdType="pubmed">11287553</ArticleId></ArticleIdList></Reference><Reference><Citation>Galula J. U., Shen W. F., Chuang S. T., Chang G. J. and Chao D. Y.(2014). Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol 88(18): 10813-10830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178884</ArticleId><ArticleId IdType="pubmed">25008922</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes D. A., Purdy D. E., Chao D. Y., Noga A. J. and Chang G. J.(2005). Comparative analysis of immunoglobulin M(IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. J Clin Microbiol 43(7): 3227-3236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169144</ArticleId><ArticleId IdType="pubmed">16000440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt A. R., Cropp C. B. and Chang G. J.(2001). A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J Virol Methods 97(1-2): 133-149.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483224</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E. and Fujii A.(2002). Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20(7-8): 1058-1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803066</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhou J., Yu Z., Fang D., Fu C., Zhu X., He Z., Yan H. and Jiang L.(2014). Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. BMC Microbiol 14: 233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396058</ArticleId><ArticleId IdType="pubmed">25520151</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W. F., Galula J. U., Liu J. H., Liao M. Y., Huang C. H., Wang Y. C., Wu H. C., Liang J. J., Lin Y. L., Whitney M. T., Chang G. J., Chen S. R., Wu S. R. and Chao D. Y.(2018). Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody. Elife 7: e38970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234032</ArticleId><ArticleId IdType="pubmed">30334522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>